Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401622 · ClinicalTrials.gov registry record · NA
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
A NA study, sponsored by LifeScan.
- Completed
- Registry status
- NA
- Development phase
- 320
- Enrollment target
NCT00401622: Completed NA study, sponsored by LifeScan.
NCT00401622 is a NA study that has completed, run by LifeScan. The registered enrollment target is 320 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00401622, a NA study, has completed, sponsored by LifeScan.
- COMPLETED
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
Study Summary
Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.
Interventions
- BEHAVIORAL Standard care
- BEHAVIORAL OneTouch® Ultra®2 System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2006-10-01 |
| Est. Completion | 2009-01-01 |
| Phase | NA |
What the finished NCT00401622 record still lists
NCT00401622 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard care is the first listed.
NCT00401622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00401622 about?
NCT00401622 is a clinical study titled "Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes". Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.
What is the current status of trial NCT00401622?
This trial is currently completed. It is a NA study. The enrollment target is 320 participants. The study started on 2006-10-01. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00401622?
The interventions under investigation include: Standard care (BEHAVIORAL), OneTouch® Ultra®2 System (BEHAVIORAL).
Who is sponsoring clinical trial NCT00401622?
This trial is sponsored by LifeScan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00401622's enrollment target sits among peer trials
320 315th of 2000 higher than 1,680 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI